Vaccine – Volume 35, Issue 4, Pages 503-712 (23 January 2017)

Vaccine
Volume 35, Issue 4, Pages 503-712 (23 January 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/4

Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted
Original Research Article
Pages 680-686
Sara L. Thomas, Jemma L. Walker, Justin Fenty, Katherine E. Atkins, Alex J. Elliot, Helen E. Hughes, Julia Stowe, Shamez Ladhani, Nick J. Andrews
Abstract
Background
Introduction of infant oral rotavirus vaccination in the UK in July 2013 has resulted in decreased hospitalisations and Emergency Department (ED) visits for acute gastroenteritis (AGE), for both adults and children. We investigated reductions in AGE incidence seen in primary care in the two years after vaccine introduction, and estimated the healthcare costs averted across healthcare settings in the first year of the vaccination programme.
Methods
We used primary care data from the Clinical Practice Research Datalink and age-stratified time-series analyses to derive adjusted incidence rate ratios (IRRa) for AGE in the first two years of the post-vaccination era (July 2013-April 2015) compared to the pre-vaccination era (July 2008-June 2013). We estimated cases averted among children aged Results
In general practice, AGE rates in infants (the target group for vaccination) decreased by 15% overall after vaccine introduction (IRRa = 0.85; 95%CI=0.76–0.95), and by 41% in the months of historically high rotavirus circulation (IRRa=0.59; 95%CI=0.53–0.66). Rates also decreased in other young children and to a lesser degree in older individuals, indicating herd immunity. Across all three settings (general practice, EDs, and hospitalisations) an estimated 87,376 (95% prediction interval: 62,588–113,561) AGE visits by children aged Conclusions
The marked decreases in the general practice AGE burden after rotavirus vaccine introduction mirror decreases seen in other UK healthcare settings. Overall, these decreases are associated with substantial averted healthcare costs.